Maté’s guidance to combine Compassionate Inquiry with Psilocybin for, say alcoholism, and create exclusivity or patent protection? Maté is one such practitioner and his methodology is called Compassionate Inquiry. In disciplines like psychotherapy, physical therapy, massage therapy the methodologies and strategies are developed by long time practitioners and taught to students in continuing education classes. We tend to think of IP in medicine in relation to chemical compounds, manufacturing, and formulation but the unique feature of psychedelic medicine is the conjoining of a pharmaceutical agent in conjunction with therapy.Ĭan psychotherapeutic protocols, strategies, and frameworks be patented? Maté, is about the relationship between therapeutic protocol development and Intellectual Property.Īs a publicly-traded company with fiduciary responsibilities Numinus is tasked with optimizing returns to their shareholders and this, in theory, involves patents. The question this raises, not specific to Numinus or Dr. "The Resulting Issuer intends to develop a framework for psychedelic therapies in a clinical test environment.The facility will be instrumental in assessing the protocols developed for treatment and will include lab space and equipment, research space, protocol testing functionality, and be able to house the R&D team." ![]() Applying this experience to the clinical day-to-day is a good indication that the Numinus clinic is taking their responsibility seriously.Īnd as we noted last week Numinus is planning clinical research: His experience as a clinician for the poor and marginalized as well as Ayahuasca retreat facilitator is truly unique. Maté’s "brand" in the addiction, trauma, and psychedelic fields is invaluable. This is the best signal that Numinus has put out to date about their long term intentions.ĭr. Maté will also use his network to enhance Numinus's collaboration with other leading researchers and groups working in mental illness, addiction and trauma treatment." Maté will be a vital resource in helping Numinus develop treatments and drive policy changes within the healthcare industry. As a Member of the Clinical Advisory Council, Dr. Maté has pioneered therapies and innovative, trauma-based approaches to mental health. "Through over 30 years' work in family practice, palliative care and addiction medicine, Dr. Numinus, the most recent psychedelic upstart to go public announced Gabor Maté has joined the Clinical Advisory Council. Impact of Effect Size of psychedelics on clinical research The interface of science and philosophy, ie Hard Problem of Consciousness, Entropic Brain Theory, etc. Price/quality trade-offs in therapist training, therapeutic options (a subcategory of Access and Affordability)īlinding and control in clinical research The interpretation, application, and role of traditional/indigenous/shamanic practices/systems Please send me an email with additions.ĭecriminalization, Deprioritization, Legalization, Medicalization (via FDA/EMA/Health Canada, etc), State-based Medicalization (ie Oregon)Ĭhanging understanding of disease causes/processes in light of psychedelic science I am working on a series of taxonomic posts of themes/questions/issues/tradeoffs that I hope to share soon.īelow is a non-exhaustive list that we’ll be grappling with for the foreseeable future. My hope for The Trip Report is that in 2, 5, 10 years’ time we’re collectively more informed, well versed, and understanding of the ecosystem by continuing to visit these topics regularly. It takes time, energy and you inevitably run into the problem of ‘you don’t know what you don’t know’. ![]() The sense-making part is the most fun, interesting, and rewarding but also the most challenging. ![]() Make sense of the news and the larger themes/questions/issues/tradeoffs that the psychedelic ecosystem will routinely encounter as it expands. Summarize and curate psychedelic related news That is because I am trying to do two things: Perhaps you’ve noticed the structure and format of these Trip Report dispatches vary from week to week.
0 Comments
Leave a Reply. |